Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tinnitus 1Ototoxicity 1Lung Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Deafness 1

Interventions

reducing agent and tunicamycin-responsive protein, human 1pembrolizumab 1olutasidenib 1epacadostat 1ebselen 1Vorinostat 1Kidney Transplantation 1Immunotherapy, Adoptive 1Immunoglobulin G 1Fluorodeoxyglucose F18 1Continuous Positive Airway Pressure 1Cell- and Tissue-Based Therapy 1A-dmDT390-bisFv(UCHT1) protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × ebselen × 30 days × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡